Aspirin Tablets

Cardio-Diabetic · Enteric-Coated Tablets · 81mg / 150mg

Trade Information

Minimum Order Qty	1,000,000 tablets
Capacity	100 Million Tablets per month
Strength	81mg / 150mg
Private Labelling	Custom branding, artwork & market-specific labelling
Lead Time	45–60 days from order confirmation
Payment Terms	LC at sight, TT (advance / against documents)
Shipping	FOB / CIF to major international ports including Mombasa, Dar es Salaam, Lagos, Durban, Manila, Phnom Penh
Pharmacopoeia	BP, USP, IP compliant

Packing Options

Blister (Alu-Alu / Alu-PVC)
Strip pack
Bottle pack (HDPE)
Hospital bulk pack
Custom packing as per buyer requirement

Regulatory & Quality

Registration Status	Registered in multiple African, Asian, CIS, and Latin American markets. Dossier available for new market registration.
Regulatory Dossiers	CTD / ACTD format dossiers available for submission to national drug authorities.
Stability Data	Zone IVa & IVb stability data available (tropical climate conditions, 30°C/65% RH & 30°C/75% RH)
WHO Prequalification	WHO-GMP Certified

Product Details

Composition	Acetylsalicylic Acid (Aspirin)
Dosage Form	Enteric-Coated Tablets
Pack Size	10x10, Bottle of 100/500/1000 / Custom packing available
Storage	Store below 30°C in a dry place, protected from light and moisture
Shelf Life	36 months from date of manufacture

Description

Aspirin (Acetylsalicylic Acid) at low doses (75-150mg) is one of the most important cardiovascular medicines globally. It is used as an antiplatelet agent to prevent heart attacks, strokes, and blood clot formation. It is listed on the WHO Model List of Essential Medicines.

Low-dose Aspirin is a cornerstone of cardiovascular disease prevention, prescribed to millions of patients worldwide for long-term secondary prevention. The enteric-coated formulation minimises gastrointestinal side effects, improving patient compliance for chronic daily use.

BioGalen manufactures Aspirin Tablets in 81mg and 150mg strengths. With the growing burden of cardiovascular disease across Africa, Asia, and the Middle East, low-dose Aspirin is one of the highest-volume cardiovascular products in these markets.

Mechanism of Action

Low-dose Aspirin works primarily as an antiplatelet agent by irreversibly acetylating and inhibiting cyclooxygenase-1 (COX-1) in platelets. This blocks the production of thromboxane A2 (TXA2), a potent promoter of platelet aggregation and vasoconstriction. Since platelets are anucleate cells and cannot synthesise new COX-1 enzyme, a single dose of Aspirin inhibits platelet function for the entire 7–10 day lifespan of the platelet. This irreversible, cumulative antiplatelet effect is why low-dose daily Aspirin (81–150mg) is effective for long-term cardiovascular prevention, even though its anti-inflammatory and analgesic effects require much higher doses. The enteric coating delays dissolution until the alkaline environment of the small intestine, reducing direct gastric mucosal damage during chronic daily use.

Indications

Secondary prevention of myocardial infarction (heart attack)
Secondary prevention of ischaemic stroke and transient ischaemic attack (TIA)
Prevention of cardiovascular events in patients with stable angina
Post-coronary artery bypass graft (CABG) and stent placement
Acute coronary syndrome (as part of initial management)
Prevention of venous thromboembolism
Pre-eclampsia prevention in high-risk pregnancies

Available Variants

Aspirin Tablet 81mg
Aspirin Tablet 150mg

Frequently Asked Questions

Why does BioGalen offer both 81mg and 150mg strengths?

Different markets and clinical guidelines recommend different low-dose Aspirin strengths. The 81mg dose is standard in markets following American cardiology guidelines (ACC/AHA), while 150mg is widely used in markets following WHO and European guidelines. By offering both strengths, BioGalen enables distributors to serve the full range of prescribing practices across their target markets.

Why is the enteric-coated formulation important for this product?

Low-dose Aspirin is taken daily for life by cardiovascular patients. Standard Aspirin can cause gastric irritation and ulceration with chronic use. The enteric coating protects the stomach lining by ensuring the tablet dissolves in the small intestine instead. For B2B buyers, enteric-coated Aspirin has higher perceived value and is the preferred formulation in hospital formularies and tender specifications.

What is the market opportunity for low-dose Aspirin in emerging markets?

Cardiovascular disease is now the leading cause of death in Africa, Asia, and the Middle East, surpassing infectious diseases. As hypertension and diabetes screening programmes expand, the demand for secondary prevention medicines like low-dose Aspirin is growing rapidly. It is a high-volume, recurring-use product with strong institutional demand.

Can low-dose Aspirin be co-distributed with other cardiovascular products?

Yes. BioGalen manufactures a complete cardiovascular portfolio including Aspirin, Clopidogrel, Atorvastatin, Metformin, and Amlodipine. Many distributors source the full range from a single manufacturer to simplify logistics, regulatory submissions, and supplier management. Contact us for portfolio pricing.

Interested in Aspirin Tablets?

Get competitive pricing for bulk orders, private labelling, and contract manufacturing.

WhatsApp Enquiry Contact Us

Browse Categories

Browse by Dosage Form